Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: drug intervention: pentoxifylline 800mg will be given to patients of schizophrenia for 8 weeks and blood samples will be collected at baseline, 4 weeks and 8 weeks for levels of IL-6, T
Sponsors
Central institute of Psychiatry
Eligibility
Inclusion criteria
Inclusion criteria: 1. Inpatients satisfying the ICD 10- DCR (1993) criteria for Schizophrenia with duration of illness of more than 2 years 2. Age 18 to 50 years. 3. Score on MoCA less than 26. 4. CDSS score less than or equal to 6. 5. Patients who give written informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: 1. Any other major comorbid psychiatric diagnosis or significant concurrent medical illnesses. 2. Substance dependence in the last 6 months (excluding nicotine & caffeine). 3. Pregnant or lactating female patients. 4. Patients with organic brain disorder and/or mental retardation. 5. Patients on treatment with medications that can influence cognitive functioning: Anticholinergics (except trihexyphenidyl), 1st generation antipsychotics. 6. Patients on treatment with SSRI, SNRI, TCA or MAOI. 7. Patients who have received ECT in the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in levels of TNF- alpha, IL-6, BDNF as marker of improvement in inflammation on Tab. Pentoxifylline 800mg/d.Timepoint: 0 weeks, 4 weeks, 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in cognititve deficits measured by CANTAB, MoCA with Tab. Pentoxifylline 800mg/d.Timepoint: 0 weeks, 4 weeks, 8 weeks | — |
Countries
India
Contacts
Public ContactDr Surendra Paliwal
Central institute of Psychiatry
Outcome results
None listed